Refine your search
- United Kingdom (958)
- Netherlands (357)
- Germany (131)
- Spain (102)
- France (49)
- Italy (39)
- Ireland (28)
- Cyprus (24)
- Switzerland (21)
- Sweden (17)
- Blended studies (983)
- Fully online studies (864)
Certificate Principles of Identifying and Recognizing Adverse Events and Safety Signals
| Start date: |
| Tuition Fee: |
| Duration: | 3 months (3 ECTS) |
Objectives: To enable students to develop an understanding of current practice in identifying adverse drug reactions and safety signals. To be able to classify events, identify signals and understand the follow-up procedure
Certificate Drug Utilisation Studies: Introduction and Quantitative Methods
| Start date: |
| Tuition Fee: |
| Duration: | 3 months (3 ECTS) |
Objectives: To understand the need to study how medicines are used. To describe the general characteristics of the different methods to study the use of medicines, and to identify them. To know the different methods and measures that allow quantitative approach to medicines utilisation.
Certificate Case Studies in Medicines Risk Communication
| Start date: |
| Tuition Fee: |
| Duration: | 2 months (3 ECTS) |
Objectives; To analyse and discuss notable examples with special attention to the risk communication aspects. To analyse the role of media, internet, scientific journals, independent bulletin of information. To measure the effectiveness of risk communication as a minimisation strategy and consider ways of improving its effectiveness.
Certificate Methods in Clinical Research, Pharmacoepidemiology and in the Assessment of the Efficacy of Medicines
| Start date: |
| Tuition Fee: |
| Duration: | 3 months (3 ECTS) |
Objectives: To develop a robust knowledge and familiarity with the methods used in clinical research and pharmacoepidemiology to evaluate the efficacy and effectiveness of medicines and therapeutic interventions. To develop a robust knowledge and familiarity with the methods used in randomised clinical trials.
M.Sc. Pharmacovigilance and Pharmacoepidemiology (Master Year 1)
| Start date: |
| Tuition Fee: |
| Duration: | 12 months (60 ECTS) |
The Eu2P Master is an academic post-graduate diploma in pharmacovigilance and pharmacoepidemiology jointly delivered by Eu2P Academic Partners. This European diploma is awarded under the authority of each national Ministry of Higher Education or ad hoc authority. The Eu2P Master is both supported and recognised by Eu2P regulatory and industrial partners.
Certificate Principles of Pharmacovigilance
| Start date: |
| Tuition Fee: |
| Duration: | 3 months (3 ECTS) |
Objectives: To enable trainees to develop an understanding of the principles of pharmacovigilance from the development of the science to its place in pre and post-marketing environment and the roles of various stakeholders within pharmacovigilance.
M.Sc. Pharmacovigilance and Pharmacoepidemiology (Master Year 2)
| Start date: |
| Tuition Fee: |
| Duration: | 12 months (60 ECTS) |
The Eu2P Master is an academic post-graduate diploma in pharmacovigilance and pharmacoepidemiology jointly delivered by Eu2P Academic Partners. This European diploma is awarded under the authority of each national Ministry of Higher Education or ad hoc authority. The Eu2P Master is both supported and recognised by Eu2P regulatory and industrial partners.
Certificate Information and Communication About Benefit-risk of Medicines. Basic Principles.
Certificate Pharmacovigilance Regulations
| Start date: |
| Tuition Fee: |
| Duration: | 3 months (3 ECTS) |
Objectives: To enable trainees to develop an understanding of European, USA and major local and worldwide regulations and guidelines concerning pharmacovigilance. Emphasis will be placed on the problems of interpretation of pharmacovigilance regulations both pre- and post-marketing.
Certificate The Public Health Impact of Adverse Drug Reactions
| Start date: |
| Tuition Fee: |
| Duration: | 2 months (3 ECTS) |
Objectives: To critically use data from experimental and observational studies to evaluate the public health impact of selected adverse drug reactions. To design and to carry out an analysis of the impact of adverse effects at a community level. To analyse the economic impact of adverse drug reactions on public health.
